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Vascular calciﬁcation is common in ESRD patients and is important in increasing mortality from cardiovascular complications
in these patients. Hyperphosphatemia related to chronic kidney disease is increasingly known as major stimulus for vascular
calciﬁcation. Hyperphosphatemia and vascular calciﬁcation become popular discussion among nephrologist environment more
than ﬁve decades, and many researches have been evolved. Risk factors for calciﬁcation are nowadays focused for the therapeutic
prevention of vascular calciﬁcation with the hope of reducing cardiovascular complications.
1.Introduction
Vascular calciﬁcation is a kind of extraosseous calciﬁca-
tion and is associated with aging physiologically, and a
number of disorders including ESRD, diabetes mellitus,
andcardiovasculardiseasepathologically.Multifactorialpro-
cesses contribute to VC in which derangements in calcium
and phosphorus homeostasis plays an important role and
becomes popular therapeutic target nowadays. In ESRD
patients with vascular calciﬁcation, a mixture of intimal
and medial calciﬁcation has been observed in the eﬀected
vessels with dominant medial involvement. The risk of CVD
mortality in ESRD patients with vascular calciﬁcation is 20
to 30 times higher than that of the general population [1–5].
Although phosphate is important for diverse cellular
and physiological functions, impaired renal function with
resultant phosphate accumulation with consequent bone
and mineral disorders and vascular calciﬁcation are major
problems among nephrologists. The increased risk of CVD
mortality by hyperphosphatemia was partially explained by
the predisposition of this population to vascular calciﬁcation
[6–8].(Figure 1)EveninearlystageCKD,serumphosphorus
level disturbances are proved to promote vascular calciﬁca-
tion, hypertension, myocardial hypertrophy, and heart fai-
lure [9–11]. Current understanding of relationship between
phosphorus and those disorders becomes popular in medical
ﬁeld, with the hope of halting or retarding the vascular
calciﬁcation from the very early status in those patients.
2. TraditionalConcepts inESRD
Patients withVascular Calciﬁcation
2.1. Vascular Calciﬁcation in ESRD Patients. Vascular cal-
ciﬁcation (VC), an extra osseous calciﬁcation of arteries,
is strongly associated with CKD patients with or without
hemodialysis. Two types of VC include neointimal calciﬁ-
cation, which occurs in large and medium-sized arteries,
and medial calciﬁcation, which occurs in arteries of any
size, including arterioles. VC is an important indicator of
atherosclerosis, and its occurance directly predict progno-
sis of atherosclerotic disease [12]. Uremic atherosclerotic
plaques are more calciﬁed and ﬁbroatheromatous than those
in aging, with similar cellular inﬁltrates [13]a n dm o r eo f
tunica media involvement [14, 15]. VC in ESRD patients,
those especially found in the tunica media of large arteries,
may lead to increased stiﬀening and decreased compliance of
thesevessels.Consequentincreasedarterialpulsewaveveloc-
ity, pulse pressure, and impair arterial dispensability result2 International Journal of Nephrology
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Figure 1: Mechanisms of VSMC osteogenesis during vascular calciﬁcation in chronic kidney disease. VSMC upregulate expression of
transcription factors Osf2/Cbfa1 which were enhanced by ROS, leptin, vitamin D, increased CaxP product, or high PO4 (Pi) levels induced
by Pit-1. VSMC activation occurs in part as a result of the phenotypic switch of VSMCs into osteoblast-like cells. VSMCs that have acquired
an osteogenic phenotype express ALP and produce hydroxyapatite crystals. Calciﬁcation inhibitors such as PPi inhibit hydroxyapatite
precipitation, whereas fetuin-A, MGP, OPG, OPN, and BMP-7 antagonize calciﬁcation. VSMC: Vascular smooth muscle cells, Osf2/Cbfa1:
Osteoblast-speciﬁctranscriptionfactor,ROS:Reactiveoxygenspecies,CaxPproduct:Calciumxphosphateproduce,PO4(Pi):Phosphate,Pit-
1: Sodium-phosphate cotransporter-1, ALP: Alkaline phosphatase, PPi: Pyrophosphate, MGP: Matrix Gla protein, OPG: Osteoprotegerin,
OPN: Osteopontin, BMP: Bone morphogenic protein.
in increase afterload and left ventricular hypertrophy, which
ﬁnally compromise coronary perfusion with development of
congestive heart failure [7, 10, 16–19].
2.2. Risk Factors of Vascular Calciﬁcation in ESRD Patients.
Risk factors for premature VC in ESRD patients are diﬀerent
from the traditional atherogenic risk factors. Hyperparathy-
roidism and alteration in Ca-P mineral metabolism, espe-
cially hyperphosphatemia, modulate renal osteodystrophy
and vascular medial calciﬁcation [20, 21]. Microinﬂam-
mation with chronically elevated acute phase protein CRP
relates with intimal calciﬁcation and predicts the CV mor-
tality. The presence of C. pneumoniae in arterial walls and
atherosclerotic lesions also related this persistant infection
with atherosclerotic vascular lesions in CKD with or without
dialysis patients [13, 19]. Longer hemodialysis duration is
also found to be signiﬁcantly relate with severe vascular
calciﬁcation [4, 5, 21, 22]. Furthermore, hyperglycemia and
hyperphosphatemia are two most signiﬁcant factors to be
considered in ESRD patients with and without diabetes
mellitus, respectively [23].
2.3. Role of Phosphate in ESRD with Vascular Calciﬁcation.
Serumphosphateconcentrationisusuallymaintainedwithin
2.5 to 4.5mg/dL by a variety of mechanisms until renal dis-
ease has progressed to approximately CKD stage 5 or ESRD
[24, 25]. Adaptation of nephrons in attempt to preserve
phosphate homeostasis in ESRD patients plays an important
role for VC. Hyperphosphatemia result in secondary hyper-
parathyroidism, calcium and vitamin D derangements, vas-
cular calciﬁcation, and mineral bone disorders. Additionally,
hyperparathyroid state and altered vitamin D status in ESRD
patients also play a major role in extraosseous calciﬁcations
[1, 26–28]. Higher serum phosphorus levels may increase
serum PTH levels even in healthy individuals [29]. Our
previous study revealed serum PTH levels may stimulate
inﬂammatory marker IL-6 production in HD patients [30,
31]. Higher levels of serum IL-6 and hsCRP also associated
with increased VC and CVD risk. Higher serum phosphorus
levels also inhibit 1,25-dihydroxyvitamin D synthesis [32,
33]. Lower 1,25-dihydroxyvitamin D status was associated
withmyocardialdysfunction[27,34]andincreasedcoronary
vascularcalciﬁcation[26,27,35].TheeﬀectsofvitaminDon
vascular calciﬁcation are biphasic pattern with both excess,
and deﬁciency may promote its development [17].
2.4. Mechanism of Vascular Calciﬁcation. Vascular calciﬁ-
cation involves two distinct events, smooth muscle cellInternational Journal of Nephrology 3
transformation and mineralization. Normally, blood vessels
express inhibitors of mineralization, like pyrophosphate,
matrix Gla protein, fetuin A, and loss of these inhibitors may
result in spontaneous vascular calciﬁcation. Fetuin A also
plays a role in inhibition of CaxP precipitation [36].
The presence of bone-like tissue including osteoblast-
like cells and hematopoietic elements within atherosclerotic
plaque suggest VC as osteogenic diﬀerentiation of vessel wall
cells [37–40]. A signal from AS plaque induces expression of
potent osteogenic diﬀerentiation factor BMP-2a, with bone
matrix and calcium hydroxyapatite crystals deposition in the
arterial wall cells [41, 42]. Osteoprotegerin (OPG) [43, 44]
inactivates the osteoclasts by blocking RANK activation. In
dialysispatients,serumOPGlevelsareassociatedandpredict
progressive vascular calciﬁcation especially when CRP level
is increased. Unregulated, degenerative calciﬁcation process
withinadvancedASplaqueisprogressiveandsevereinESRD
patients.
Hyperphosphatemia plays a very important role in
ESRD related arteropathy [6, 7, 45]. In hyperphosphatemic
environment (P > 2.4mM), the vascular smooth muscle
cell culture systems revealed both osteochondrogenic pheno-
typic change and mineralization through sodium-dependent
phosphate cotransporter, Pit-1 [39, 46, 47]. There was loss of
smooth muscle-speciﬁc gene expression and upregulartion
of bone diﬀerentiation genes that translate into diﬀerential
factors (Osteocalcin, osteopontin and Runx2, etc.), with the
resultant osteogenic diﬀerentiation. Calcium deposition also
occurs in prolonged hypercalcemic (>2.6mM) environment.
Calcium increases Pit-1 mRNA levels, increases smooth
muscle cell sensitization to phosphorus, and results in
osteoblastic diﬀerentiation. Elevated serum calcium was also
associatedwithelevatedCaxPproduct,alteredalkalinephos-
phatase, and decreased marix Gla protein, which together
play a role in VC [48].
Recent study revealed that calcium phosphate deposition
may trigger the osteogenic changes. Calcium phosphate
deposition (CPD) occurs as a cellular independent pheno-
menon which depends on calcium, phosphate, and hydroxyl
ionsconcentration,butnotonCaxPiconcentrationproducts
[49]. A mouse lacking the VC inhibitor matrix-Gla pro-
tein had spontaneous extensive extraosseous calciﬁcations
despitenormalCaandPconcentrations[50].Mineralization
is actively inhibited and prevented in the arteries. The loss
of calciﬁcation inhibitors and CPD may lead to speciﬁc
o s t e o g e n ee x p r e s s i o na n dV S M Cd i ﬀerentiation and ﬁnally
result in vascular calciﬁcation [49].
A genetic mechanism of hyperphosphatemia on vascular
calciﬁcation was cited by Wu-Wong et al. in 2007. Elevated
P modulates through VDR mRNA stability and PPARγ-
mediated gene expression may lead to its detrimental eﬀects
including vascular calciﬁcation [20].
The calcium-sensing receptor (CaSR), which is expressed
in vascular wall, plays key role in inhibition of vascular
calciﬁcation in patients with chronic kidney disease (CKD).
After CaSR stimulation, many intracellular signaling events
occur via MEK1/ERK1,2 and PLC pathways and lead to pro-
liferation of vascular smooth muscle cells. CaSR-mediated
PLC activation is important for SMC survival and protection
against apoptosis [51, 52]. Calcimimetic agents act on
CaSR increasingly known nowadays for treatment of SHPT
and CKD-MBD. Calcimimetics activate vascular calcium-
sensingreceptorandmodulatetheexpressionofVCinhibitor
proteins like matrix Gla [53]. Calcimimetics were shown to
have better plasma PTH controlling than calcitriol in uremic
rats [54]. It also revealed that combination of Calcimimetics
with calcitriol prevents VC and reduced mortality. Apart
from controlling serum PTH levels, these agents also reduce
calcium(Ca),phosphate(P),andCaxPproductlevels,which
is more beneﬁcial than other calcium containing phosphate
binders and vitamin D analogues [53, 54]. These studies
revealed that those agents may even reverse some vascular
abnormalities in CKD.
3. Contemporary Concepts inESRDPatients
with Vascular Calciﬁcation
3.1. Role of Inﬂammation and Oxidative Stress. HD patients
with secondary hyperparathyroidism may be under an
environment of increased serum inﬂammatory cytokines
and oxidative stress [30, 55]. High PTH levels, inﬂamma-
tion, and oxidative stress may involve together in CKD-
MBD and cardiovascular calciﬁcation in SHP patients. Our
recent study showed calcitriol can eﬀectively suppress PTH
secretion and reduce inﬂammatory markers including CRP
and IL-6 [31]. While using vitamin D analogues in CKD
patients, we have to note that, on one side, with increasing
survival beneﬁt, and on the other side, with some risks of
vascular calciﬁcation. Thus, vitamin D in its form of less
hypercalcemic agent paricalcitol, combination therapy with
calcimimetic agents is becoming popular nowadays. Zhao et
al. [56] demonstrate recently that increased mitochondrial
membrane potential may lead to intracellular and mito-
chondrial reactive oxygen species (ROS) stimulation, with
resultant superoxide production, and increased oxidative
stress. These ROS mediate p65 nuclear translocation which
is found to associate with phosphate-induced VC [56].
Osteogenicdiﬀerentiationfactorbonemorphogenicprotein-
2a (BMP-2a), a well-known mediator of VC, is nowadays
found to be a molecular link between oxidative stress and
arterial stiﬀness due to vascular calciﬁcation [41, 57].
3.2. FGF23-Klotho Axis. The ﬁbroblast growth factor–23
(FGF-23) and klotho genes are growingly known to regulate
phosphate homeostasis recently [58]. Fibroblast growth
factor-23 inhibits proximal renal and intestinal phosphorus
absorptionandklothogeneexpressinrenaldistalconvoluted
tubules and parathyroid gland. In mice, deletions of klotho
a n dF G F - 2 3g e n e sf o u n dt or e s u l ti nh y p e r p h o s p h a e m i a ,
vascular calciﬁcation, arteriosclerosis, elevated 1,25(OH)2D,
and osteopenia.
Patients with CKD have elevated FGF-23 levels early in
the course of disease before clinically signiﬁcant hyperphos-
phatemia occurs. Increased circulating FGF-23 target the
remnantnephrons,enhancephosphateexcretion,andinhibit
1,25(OH)2D3 production. Thus, frank hyperphosphatemia
does not develop until GFR < 30mL/min. FGF-23 con-
centrations directly correlate with renal function. Higher4 International Journal of Nephrology
FGF-23 levels indicate rapidly progressive CKD, and also
predict mortality in HD patient, thus, FGF-23 level may
become important as creatinine level in kidney function
assessment in future [59]. FGF-23 in earlier CKD increase
phosphate excretion and prevent the development of vascu-
lar calciﬁcation. Higher FGF-23 also lead to reduced serum
levels of 1,25(OH)2D in early CKD despite high PTH.
Its phosphaturic and hypovitaminosis D eﬀects are more
important than PTH in earlier stages of CKD. The resultant
low serum 1,25(OH)2D and hypocalcemia enhance PTH
secretion and progress to secondary hyperparathyroidism.
FGF-23, together with cofactor klotho, act on FGF receptor
in parathyroid gland and reduce its secretion. But, in later
stages of CKD, FGF23 resistance and hyperphosphatemia
lead to secondary HPTH despite high FGF23 levels. Due to
progressive nephron loss, the number of nephrons responds
to FGF-23 reduced and phosphate retension occurs in
late stage CKD. Abnormally high FGF23 levels in later
stages of CKD lead to vascular dysfunction, left ventricular
hypertrophy, and early mortality. Aortic calciﬁcation can
be predicted by measuring FGF-23 level in hemodialysis
patients [60]. Phosphate binders or use of long-acting PTH
analogs to reduce intestional phosphate reabsorption in
earlier stages CKD may reduce FGF-23 production and
prevent those complications. In future, FGF-23 may be an
important therapeutic target in management of CKD and
hyperphosphatemia.
3.3. Role of Metabolic Acidosis. Metabolic acidosis which is
very common in CKD patients may lead to bone dissolution
by osteoclast activation and osteoblast inhibition [61, 62].
Our studies prove that acute correction of metabolic acidosis
improves osteoblast function, increases 1,25(OH)2D3 levels,
and attenuates circulating PTH activity in chronic renal fail-
urepatients,anditunderlinestheimportanceofmaintaining
normal acid-base homeostasis in chronic renal failure [63–
65]. Mendoza et al. [66] hypothesize an assumption that the
response of extraosseous calciﬁcation to metabolic acidosis
may be similar to that of bone, and, given that metabolic
acidosis impairs bone mineralization, it is likely to attenuate
the extraosseous calciﬁcation processes. They investigate the
in vivo eﬀect of metabolic acidosis on the development
of vascular and other soft-tissue calciﬁcations in a rodent
model of uremia. Their results show that metabolic acidosis
eventually prevents the development of calcitriol-induced
extraskeletal calciﬁcations in uremic rats, even with elevated
plasma Ca and P levels. Metabolic acidosis plays a complex
mechanism in VC, including stimulating of the solubility of
Ca-P deposits, suppressing parathyroid secretion, inhibiting
some osteogenic enzymes, blocking bone matrix formation,
modulating the upregulation of Pit-1, and ﬁnally blocking
phosphate uptake by the arterial smooth muscle cells [61].
3.4.RoleofAdipocytokineLeptin. IncreasedBMIandabdom-
inal obesity are well known to be related with metabolic syn-
drome and cardiovascular complications. Mediators released
from adipose tissue are recently shown to be playing a role
in promoting CVD. It has been shown in our previous
study that adipocytokine leptin level is a marker for body
adiposity in hemodialysis patients [67]. Studies conducted
by Zeadin et al. [68] and Martin et al. [69] showed that a
positive correlation between plasma leptin levels and CAC.
It has been demonstrated that leptin promote osteoblastic
diﬀerentiation of vascular smooth muscle cells and, thus,
possibly lead to vascular calciﬁcation.
3.5. Role of Salivary Phosphate. In uremic patients, hyper-
phosphatemia is found to be poorly controlled even with the
use of phosphate binders and dietary phosphate limitation
in addition to dialysis. Savica et al. [70] found the role
of salivary phosphate in worsening hyperphosphatemia in
CKD patients. The salivary phosphorus ratio in dialysis
patients was more than two times compared with healthy
controls, and salivary phosphorus was ﬁve times higher
than serum phosphorus in those patients. Thus, salivary
phosphate binders could be an eﬃcient approach in treating
hyperphosphatemia in those patients.
3.6. Role of Pyrophosphate. Recent data suggest that deﬁcient
in pyrophosphate (PPi), a potent inhibitor of vascular
calciﬁcation, may increase the medial vascular calciﬁcation
in advanced kidney disease [71]. Levels of PPi are reduced in
hemodialysis patients [72]. Hydrolysis of PPi is increased in
aortas from uremic rats because of upregulation of alkaline
phosphatase, providing a mechanism for vascular deﬁciency
ofPPi.Therefore,thedatasuggestthatexogenousPPimaybe
useful in treating or preventing uremic vascular calciﬁcation.
O’Neill and colleagues [73] show in uremic rats that sys-
temic administration of pyrophosphate prevents or reduces
uremia-related vascular calciﬁcation, without overt negative
consequences for bone and without calcium pyrophosphate
deposition disease. These ﬁndings prompt further research
into the potential of pyrophosphate as treatment for vascular
calciﬁcation in chronic kidney disease patients.
3.7. New Concept on Measures to Halt Phosphorus-Related
Vascular Calciﬁcation. Factors that relate with vascular
calciﬁcation process in CKD patients include phosphorus
activationofthePit-1receptor,bonemorphogenicproteins2
and4,leptin,endogenous1,25dihydroxyvitaminD,vascular
calciﬁcation activating factor, and measures of oxidative
stress. These entities may become future targets for diagnosis
and treatment since standard hydroxymethylglutaryl-CoA
reductase inhibitors have been shown to be failing to
attenuate the progressive VC in those patients.
Dietary and therapeutic phosphorus control stands out
as an important and basic step of preventing progressive
VC in CKD patients. Dietary phosphorus control plays an
important regulatory role in mineral homeostasis. Phospho-
rus is absorbed throughout the intestines and via 2 separate
processes, a sodium-independent paracellular pathway and
sodium-dependent carrier-mediated transcellular pathway
(NaP-IIb) [74]. Low dietary phosphorus level may increase
that type II b Na-P cotransporters protein expression on
enterocytes with increasing P absorption. The percentage
of dietary absorption varies with intake. At high levels ofInternational Journal of Nephrology 5
intake (>10mg/kg/day), approximately 70% of the ingested
P is absorbed, whereas at lower levels of intake, as much as
80%–90% may be absorbed. Net intestional P absorption
may be somewhat lowered in patients with ESRD. Inorganic
phosphate is an important P which is found mostly in food
additives like enhanced meat products, cereal and snack
bars, ﬂavored waters, and frozen meals, with 90% to 100%
absorption. Thus, the principle of Pi management in ESRD
patients is to restrict dietary Pi intake to 1∼1.4g/day, usage
of phosphate binders as needed, and if still noncompliant
can increase the dialysis time (Nocturnal HD) and frequency
(ShortDailyHD)withtargetlevelsofPi<4.6mg/dLinCKD
stage 3,4 and 3.5–5.5mg/dL in CKD stage 5.
With concept of insuﬃcient phosphorus removal by
conventional hemodialysis, phosphate binders are taking to
reduce gastrointestional phosphate absorption by virtually
all hemodialysis patients. Due to potential risk of VC with
calcium overload, Calcium-based phosphate binders are
nowadays replaced by non-Ca-based ones. Sevelamer HCl
[75–77] and Lanthanum carbonate [78–80] are the non-Ca-
based phosphate binders well known nowadays with beneﬁ-
cialeﬀectsonvascularcalciﬁcation.Sevelamerfoundtoexert
many beneﬁts on VC by increasing fetuin-A levels, reducing
systemic inﬂammation and modulating lipid proﬁles [81–
83]. Eﬃcacy and safety of new non-calcium, iron-based
phosphate binder SBR759 was studied by Block et al. in a
phaseIclinicaltrial.Risksofironaccumulationandhypocal-
cemia were addressed but appear to be well tolerated [84].
Pyrophosphate, serve as an endogenous inhibitor of cal-
ciﬁcation and prevent hydroxyapatite formation in the vessel
walls [85–87]. Pyrophosphate stands important defense
against calciﬁcation in vessels without adverse eﬀects on
bone [73]. Thus, pyrophosphate becomes recent popu-
lar medication research in progress. Nitrogen-containing
bisphosphonates (NCBPs) (e.g., ibandronate, alendronate,
risedronate, and zoledronate) may inhibit the cardiovascular
calciﬁcation [88, 89]. Etidronate may also reduce chronic
inﬂammatory response and decrease OPG concentrations
withtheresultantdecreaseinvascularcalciﬁcationindialysis
patients [90].
Niacin lowers serum phosphate and increases HDL
cholesterol in dialysis patients. Niaspan (prolonged-release
nicotinic acid) lowers serum phosphate and increases HDL
cholesterol in dialysis patients [91, 92]. Patients with ESRD
often have markedly elevated salivary phosphate concentra-
tion,independentoffoodcontent.Arecentstudyonthirteen
HD patients with serum phosphate levels > 6.0mg/dL
chewed 20mg of chitosan-loaded chewing gum twice daily
for 2 wk at fast in addition to oral compound found to be
a useful approach for improving treatment of hyperphos-
phatemia in HD patients [93]. An experiment on ammo-
nium chloride on uremic rats having a high phosphorus diet
and calcitriol treatment may prevent vascular calciﬁcation
[66]. This explains that the alkaline pH environment which
occurs during regular HD even for a short time may lead
to vascular calciﬁcation [94]. Thiosulfate, previously taken
for urolithiasis events, nowadays seem to reduce vascular
calciﬁcation [95]. Additional clinical trials on Thiosulfate are
still underway [96]. Vitamin K analogues serve as cofactors
for gamma-carboxylation of proteins including coagulation
factorsandmatrixglaprotein(MGP).MGPregulatevascular
calciﬁcation, and its deﬁciency may lead to severe VC and
CVD [50].
4. Conclusion
Vascular calciﬁcation started with extracellular phosphate
regulation of vascular smooth muscle cell osteogenic diﬀer-
entiation and calcium phosphate mineralization. General-
izedinﬂammatoryconditioninESRDpatientsalsosuggested
playing as an important factor in VC. FGF23-Klotho axis in
regulating serum P levels and their roles in CVD become
uncovered recently, while newer concepts of PTH and
vitamin D are still evolving. It is increasingly accepted that
factors promoting VC and inhibiting VC are in balance with
excess of any one may relate with adverse eﬀects in CKD-
MBD and VC. Management trends are shifting from treating
VC in older days to preventing VC in the new era. For the
last, but not the least, the main target for all those eﬀorts is
to improve survival and life quality of these ESRD patients.
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